Stay updated with breaking news from Samitinjoy Basak. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
There is a saying in the stock market that irrespective of whether an investor makes or loses money on a trade, the broker always makes money on it. Something similar seems to be playing out in the FMCG space
Lupin's shares declined 4 per cent in Thursday's intra-day trade despite receiving the final approval of the USFDA for inhalation drug gSpiriva
The stock of Divis Laboratories is up 10 per cent over the last couple of trading sessions on expectations that the worst is behind and the company could see a sequential growth in the March quarter of the 2022-23 financial year (Q4FY23). The stock witnessed the highest downgrades among Nifty50 index stocks with earnings cuts over a third after the Q3FY23 results. The company had posted a 32 per cent drop in revenues over the year ago quarter in Q3FY23 and 8 per cent sequentially, which was sharply lower than Street expectations.